Functions, divergence and clinical value of TAp73 isoforms in cancer

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 511-534

  Logotheti, Stella ^a   Pavlopoulou, Athanasia ^b   Galtsidis, Sotiris ^a   Vojtesek, Borek ^c   Zoumpourlis, Vassilis ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Apoptosis; C terminus; Cancer; Cell cycle arrest; DNA damage; TAp73 isoforms

Indexed keywords

ISOPROTEIN; PROLINE; PROTEIN TAP73; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; APOPTOSIS; BINDING AFFINITY; CANCER DIAGNOSIS; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHEMOSENSITIVITY; DIAGNOSTIC VALUE; DNA DAMAGE; ENERGY METABOLISM; GENE; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; P73 GENE; PRIORITY JOURNAL; PROLINE RICH PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84890312148     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9424-x     Document Type: Review

References (118)

1. Murray-Zmijewski, F., Lane, D. P., & Bourdon, J. C. (2006). p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death and Differentiation, 13(6), 962-972.
2. Rufini, A., Agostini, M., Grespi, F., Tomasini, R., Sayan, B. S., Niklison-Chirou, M. V., et al. (2011). p73 in cancer. Genes Cancer, 2(4), 491-502.
3. Ueda, Y., Hijikata, M., Takagi, S., Chiba, T., & Shimotohno, K. (1999). New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene, 18(35), 4993-4998.
4. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., et al. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90(4), 809-819.
5. Ishimoto, O., Kawahara, C., Enjo, K., Obinata, M., Nukiwa, T., & Ikawa, S. (2002). Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Research, 62(3), 636-641.
6. De Laurenzi, V., Costanzo, A., Barcaroli, D., Terrinoni, A., Falco, M., Annicchiarico-Petruzzelli, M., et al. (1998). Two new p73 splice variants, gamma and delta, with different transcriptional activity. The Journal of Experimental Medicine, 188(9), 1763-1768.
7. De Laurenzi, V. D., Catani, M. V., Terrinoni, A., Corazzari, M., Melino, G., Costanzo, A., et al. (1999). Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death and Differentiation, 6(5), 389-390.
8. Zaika, A. I., Kovalev, S., Marchenko, N. D., & Moll, U. M. (1999). Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Research, 59(13), 3257-3263.
9. Scaruffi, P., Casciano, I., Masiero, L., Basso, G., Romani, M., & Tonini, G. P. (2000). Lack of p73 expression in mature B-ALL and identification of three new splicing variants restricted to pre B and C-ALL indicate a role of p73 in B cell ALL differentiation. Leukemia, 14(3), 518-519.
10. Coates, P. J. (2006). Regulating p73 isoforms in human tumours. The Journal of Pathology, 210(4), 385-389.
11. Romani, M., Tonini, G. P., Banelli, B., Allemanni, G., Mazzocco, K., Scaruffi, P., et al. (2003). Biological and clinical role of p73 in neuroblastoma. Cancer Letters, 197(1-2), 111-117.
12. Casciano, I., Ponzoni, M., Lo Cunsolo, C., Tonini, G. P., & Romani, M. (1999). Different p73 splicing variants are expressed in distinct tumour areas of a multifocal neuroblastoma. Cell Death and Differentiation, 6(5), 391-393.
13. Tschan, M. P., Grob, T. J., Peters, U. R., Laurenzi, V. D., Huegli, B., Kreuzer, K. A., et al. (2000). Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochemical and Biophysical Research Communications, 277(1), 62-65.
14. Rizzo, M. G., Giombini, E., Diverio, D., Vignetti, M., Sacchi, A., Testa, U., et al. (2004). Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia, 18(11), 1804-1809.
15. Zwahlen, D., Tschan, M. P., Grob, T. J., Peters, U. R., Fink, D., Haenggi, W., et al. (2000). Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. International Journal of Cancer, 88(1), 66-70.
16. Logotheti, S., Michalopoulos, I., Sideridou, M., Daskalos, A., Kossida, S., Spandidos, D. A., et al. (2010). Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer. FEBS Journal, 277(14), 3014-3027.
17. Nenutil, R., Ceskova, P., Coates, P. J., Nylander, K., & Vojtesek, B. (2003). Differential expression of p73alpha in normal ectocervical epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma. International Journal of Gynecological Pathology, 22(4), 386-392.
18. Puig, P., Capodieci, P., Drobnjak, M., Verbel, D., Prives, C., Cordon-Cardo, C., et al. (2003). p73 expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clinical Cancer Research, 9(15), 5642-5651.
19. Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., et al. (2000). p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature, 404(6773), 99-103.
20. Nemajerova, A., Palacios, G., Nowak, N. J., Matsui, S., & Petrenko, O. (2009). Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis. PLoS One, 4(11), e7784.
21. Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., et al. (2005). Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell, 7(4), 363-373.
22. Tomasini, R., Tsuchihara, K., Wilhelm, M., Fujitani, M., Rufini, A., Cheung, C. C., et al. (2008). TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes & Development, 22(19), 2677-2691.
23. Wilhelm, M. T., Rufini, A., Wetzel, M. K., Tsuchihara, K., Inoue, S., Tomasini, R., et al. (2010). Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway. Genes & Development, 24(6), 549-560.
24. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57-70.
25. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674.
26. Klanrit, P., Taebunpakul, P., Flinterman, M. B., Odell, E. W., Riaz, M. A., Melino, G., et al. (2009). PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. Oncogene, 28(39), 3499-3512.
27. Yamamura, Y., Lee, W. L., Goh, M. X., & Ito, Y. (2008). Role of TAp73alpha in induction of apoptosis by transforming growth factor-beta in gastric cancer cells. FEBS Letters, 582(17), 2663-2667.
28. Ramadan, S., Terrinoni, A., Catani, M. V., Sayan, A. E., Knight, R. A., Mueller, M., et al. (2005). p73 induces apoptosis by different mechanisms. Biochemical and Biophysical Research Communications, 331(3), 713-717.
29. Chakraborty, J., Banerjee, S., Ray, P., Hossain, D. M., Bhattacharyya, S., Adhikary, A., et al. (2010). Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cells. The Journal of Biological Chemistry, 285(43), 33104-33112.
30. Tophkhane, C., Yang, S. H., Jiang, Y., Ma, Z., Subramaniam, D., Anant, S., et al. (2012). p53 inactivation upregulates p73 expression through E2F-1 mediated transcription. PLoS One, 7(8), e43564.
31. Melino, G. (2003). p73, the "assistant" guardian of the genome? Annals of the New York Academy of Sciences, 1010, 9-15.
32. Ozono, E., Komori, H., Iwanaga, R., Tanaka, T., Sakae, T., Kitamura, H., et al. (2012). Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts. Genes to Cells, 17(8), 660-672.
33. Beitzinger, M., Hofmann, L., Oswald, C., Beinoraviciute-Kellner, R., Sauer, M., Griesmann, H., et al. (2008). p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. The EMBO Journal, 27(5), 792-803.
34. Zhang, Y., Yan, W., Jung, Y. S., & Chen, X. (2012). Mammary epithelial cell polarity is regulated differentially by p73 isoforms via epithelial-to-mesenchymal transition. The Journal of Biological Chemistry, 287(21), 17746-17753.
35. Boominathan, L. (2010). The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer and Metastasis Reviews, 29(4), 613-639.
36. Beitzinger, M., Oswald, C., Beinoraviciute-Kellner, R., & Stiewe, T. (2006). Regulation of telomerase activity by the p53 family member p73. Oncogene, 25(6), 813-826.
37. Díaz, R., Peña, C., Silva, J., Lorenzo, Y., García, V., García, J. M., et al. (2008). p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. International Journal of Cancer, 123(5), 1060-1067.
38. Rufini, A., Niklison-Chirou, M. V., Inoue, S., Tomasini, R., Harris, I. S., Marino, A., et al. (2012). TAp73 depletion accelerates aging through metabolic dysregulation. Genes & Development, 26(18), 2009-2014.
39. Siu, L. L., Chan, J. K., Wong, K. F., & Kwong, Y. L. (2002). Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. The American Journal of Pathology, 160(1), 59-66.
40. Tomasini, R., Secq, V., Pouyet, L., Thakur, A.K., Wilhelm, M., Nigri, J., et al. (2013). TAp73 is required for macrophage-mediated innate immunity and the resolution of inflammatory responses. Cell Death & Differentiation, 20(2), 293-301.
41. Tomasini, R., Tsuchihara, K., Tsuda, C., Lau, S. K., Wilhelm, M., Ruffini, A., et al. (2009). TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proceedings of the National Academy of Sciences of the United States of America, 106(3), 797-802.
42. Lee, J. H., & Sancar, A. (2011). Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 108(26), 10668-10772.
43. Ramsey, M. R., & Ellisen, L. W. (2011). Circadian function in cancer: regulating the DNA damage response. Proceedings of the National Academy of Sciences of the United States of America, 108(26), 10379-10380.
44. Marabese, M., Vikhanskaya, F., & Broggini, M. (2007). p73: a chiaroscuro gene in cancer. European Journal of Cancer, 43(9), 1361-1372.
45. Ueda, Y., Hijikata, M., Takagi, S., Chiba, T., & Shimotohno, K. (2001). Transcriptional activities of p73 splicing variants are regulated by inter-variant association. Biochemical Journal, 356(Pt 3), 859-866.
46. Zoric, A., Horvat, A., & Slade, N. (2013). Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis, 34(3), 522-529.
47. Holcakova, J., Ceskova, P., Hrstka, R., Muller, P., Dubska, L., Coates, P. J., et al. (2008). The cell type-specific effect of TAp73 isoforms on the cell cycle and apoptosis. Cellular and Molecular Biology Letters, 13(3), 404-420.
48. Müller, M., Schilling, T., Sayan, A. E., Kairat, A., Lorenz, K., Schulze-Bergkamen, H., et al. (2005). TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death and Differentiation, 12(12), 1564-1577.
49. Kanaya, T., Kyo, S., Hamada, K., Takakura, M., Kitagawa, Y., Harada, H., et al. (2000). Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clinical Cancer Research, 6(4), 1239-1247.
50. Xu, D., Wang, Q., Gruber, A., Björkholm, M., Chen, Z., Zaid, A., et al. (2000). Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene, 19(45), 5123-5133.
51. Koutsodontis, G., Vasilaki, E., Chou, W. C., Papakosta, P., & Kardassis, D. (2005). Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochemical Journal, 389(Pt 2), 443-455.
52. Racek, T., Mise, N., Li, Z., Stoll, A., & Pützer, B. M. (2005). C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. The Journal of Biological Chemistry, 280(49), 40402-40405.
53. Harms, K. L., & Chen, X. (2005). The C terminus of p53 family proteins is a cell fate determinant. Molecular and Cellular Biology, 25(5), 2014-2030.
54. Koeppel, M., van Heeringen, S. J., Kramer, D., Smeenk, L., Janssen-Megens, E., Hartmann, M., et al. (2011). Crosstalk between c-Jun and TAp73alpha/beta contributes to the apoptosis-survival balance. Nucleic Acids Research, 39(14), 6069-6085.
55. Klanrit, P., Flinterman, M. B., Odell, E. W., Melino, G., Killick, R., Norris, J. S., et al. (2008). Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle, 7(2), 205-215.
56. Nyman, U., Sobczak-Pluta, A., Vlachos, P., Perlmann, T., Zhivotovsky, B., & Joseph, B. (2005). Full-length p73alpha represses drug-induced apoptosis in small cell lung carcinoma cells. The Journal of Biological Chemistry, 280(40), 34159-34169.
57. Niikura, Y., Ogi, H., Kikuchi, K., & Kitagawa, K. (2010). BUB3 that dissociates from BUB1 activates caspase-independent mitotic death (CIMD). Cell Death and Differentiation, 17(6), 1011-1024.
58. Vikhanskaya, F., Marchini, S., Marabese, M., Galliera, E., & Broggini, M. (2001). p73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Research, 61(3), 935-938.
59. Vikhanskaya, F., D'Incalci, M., & Broggini, M. (2000). p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Research, 28(2), 513-519.
60. Das, S., Nama, S., Antony, S., & Somasundaram, K. (2005). p73 beta-expressing recombinant adenovirus: a potential anticancer agent. Cancer Gene Therapy, 12(4), 417-426.
61. Lee, C. W., & La Thangue, N. B. (1999). Promoter specificity and stability control of the p53-related protein p73. Oncogene, 18(29), 4171-4181.
62. Wu, L., Zhu, H., Nie, L., & Maki, C. G. (2004). A link between p73 transcriptional activity and p73 degradation. Oncogene, 23(22), 4032-4036.
63. Munarriz, E., Barcaroli, D., Stephanou, A., Townsend, P. A., Maisse, C., Terrinoni, A., et al. (2004). PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Molecular and Cellular Biology, 24(24), 10593-10610.
64. Sayan, B. S., Yang, A. L., Conforti, F., Tucci, P., Piro, M. C., Browne, G. J., et al. (2010). Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proceedings of the National Academy of Sciences of the United States of America, 107(29), 12877-12882.
65. Nozell, S., Wu, Y., McNaughton, K., Liu, G., Willis, A., Paik, J. C., et al. (2003). Characterization of p73 functional domains necessary for transactivation and growth suppression. Oncogene, 22(28), 4333-4347.
66. Nyman, U., Vlachos, P., Cascante, A., Hermanson, O., Zhivotovsky, B., & Joseph, B. (2009). Protein kinase C-dependent phosphorylation regulates the cell cycle-inhibitory function of the p73 carboxy terminus transactivation domain. Molecular and Cellular Biology, 29(7), 1814-1825.
67. Liu, G., Nozell, S., Xiao, H., & Chen, X. (2004). DeltaNp73beta is active in transactivation and growth suppression. Molecular and Cellular Biology, 24(2), 487-501.
68. Marrazzo, E., Marchini, S., Tavecchio, M., Alberio, T., Previdi, S., Erba, E., et al. (2009). The expression of the DeltaNp73beta isoform of p73 leads to tetraploidy. European Journal of Cancer, 45(3), 443-453.
69. Marabese, M., Marchini, S., Sabatino, M. A., Polato, F., Vikhanskaya, F., Marrazzo, E., et al. (2005). Effects of inducible overexpression of DNp73alpha on cancer cell growth and response to treatment in vitro and in vivo. Cell Death and Differentiation, 12(7), 805-814.
70. Irwin, M. S. (2006). DeltaNp73: misunderstood protein? Cancer Biolοgy & Therapy, 5(7), 804-807.
71. Sauer, M., Bretz, A. C., Beinoraviciute-Kellner, R., Beitzinger, M., Burek, C., Rosenwald, A., et al. (2008). C-terminal diversity within the p53 family members account for differences in DNA binding and transcriptional activity. Nucleic Acids Research, 36(6), 1900-1912.
72. Takada, N., Ozaki, T., Ichimiya, S., Todo, S., & Nakagawara, A. (1999). Identification of a transactivation activity in the COOH-terminal region of p73 which is impaired in the naturally occurring mutants found in human neuroblastomas. Cancer Research, 59(12), 2810-2814.
73. Naka, M., Ozaki, T., Takada, N., Takahashi, M., Shishikura, T., Sakiyama, S., et al. (2001). Functional characterization of naturally occurring mutants (P405R and P425L) of p73alpha and p73beta found in neuroblastoma and lung cancer. Oncogene, 20(27), 3568-3572.
74. Mantovani, F., Piazza, S., Gostissa, M., Strano, S., Zacchi, P., Mantovani, R., et al. (2004). Pin1 links the activities of c-Abl and p300 in regulating p73 function. Molecular Cell, 14(5), 625-636.
75. Mantovani, F., Gostissa, M., Collavin, L., & Del Sal, G. (2004). KeePin' the p53 family in good shape. Cell Cycle, 3(7), 905-911.
76. Strano, S., Munarriz, E., Rossi, M., Castagnoli, L., Shaul, Y., Sacchi, A., et al. (2001). Physical interaction with Yes-associated protein enhances p73 transcriptional activity. The Journal of Biological Chemistry, 276(18), 15164-15173.
77. Levy, D., Adamovich, Y., Reuven, N., & Shaul, Y. (2007). The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death and Differentiation, 14(4), 743-751.
78. Miyazaki, K., Fujita, T., Ozaki, T., Kato, C., Kurose, Y., Sakamoto, M., et al. (2004). NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. The Journal of Biological Chemistry, 279(12), 11327-11335.
79. Aqeilan, R. I., Palamarchuk, A., Weigel, R. J., Herrero, J. J., Pekarsky, Y., & Croce, C. M. (2004). Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Research, 64(22), 8256-8261.
80. Ozaki, T., Naka, M., Takada, N., Tada, M., Sakiyama, S., & Nakagawara, A. (1999). Deletion of the COOH-terminal region of p73α enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells. Cancer Research, 59(23), 5902-5907.
81. Liu, G., & Chen, X. (2005). The C-terminal sterile alpha motif and the extreme C terminus regulate the transcriptional activity of the alpha isoform of p73. The Journal of Biological Chemistry, 280(20), 20111-20119.
82. Hosoda, M., Ozaki, T., Miyazaki, K., Hayashi, S., Furuya, K., Watanabe, K., et al. (2005). UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene, 24(48), 7156-7169.
83. Lehman, J. A., Waning, D. L., Batuello, C. N., Cipriano, R., Kadakia, M. P., & Mayo, L. D. (2011). Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress. The Journal of Biological Chemistry, 286(42), 36631-36640.
84. Kramer, S., Ozaki, T., Miyazaki, K., Kato, C., Hanamoto, T., & Nakagawara, A. (2005). Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells. Oncogene, 24(5), 938-944.
85. Watanabe, K., Ozaki, T., Nakagawa, T., Miyazaki, K., Takahashi, M., Hosoda, M., et al. (2002). Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. The Journal of Biological Chemistry, 277(17), 15113-15123.
86. Ozaki, T., Watanabe, K., Nakagawa, T., Miyazaki, K., Takahashi, M., & Nakagawara, A. (2003). Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB. Oncogene, 22(21), 3231-3242.
87. Minty, A., Dumont, X., Kaghad, M., & Caput, D. (2000). Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. The Journal of Biological Chemistry, 275(46), 36316-36323.
88. Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G., Jr., Levrero, M., et al. (1999). The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature, 399(6738), 806-809.
89. Yuan, Z. M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y. Y., et al. (1999). p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature, 399(6738), 814-817.
90. Agami, R., Blandino, G., Oren, M., & Shaul, Y. (1999). Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature, 399(6738), 809-813.
91. Costanzo, A., Merlo, P., Pediconi, N., Fulco, M., Sartorelli, V., Cole, P. A., et al. (2002). DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Molecular Cell, 9(1), 175-186.
92. Zeng, X., Lee, H., Zhang, Q., & Lu, H. (2001). p300 does not require its acetylase activity to stimulate p73 function. The Journal of Biological Chemistry, 276(1), 48-52.
93. Lapi, E., Di Agostino, S., Donzelli, S., Gal, H., Domany, E., Rechavi, G., et al. (2008). PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Molecular Cell, 32(6), 803-814.
94. Strano, S., Monti, O., Pediconi, N., Baccarini, A., Fontemaggi, G., Lapi, E., et al. (2005). The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Molecular Cell, 18(4), 447-459.
95. Levy, D., Adamovich, Y., Reuven, N., & Shaul, Y. (2008). Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Molecular Cell, 29(3), 350-361.
96. Urist, M., & Prives, C. (2004). The linchpin? Pin1 meets p73. Cancer Cell, 5(6), 515-517.
97. Belyi, V. A., & Levine, A. J. (2009). One billion years of p53/p63/p73 evolution. Proceedings of the National Academy of Sciences of the United States of America, 106(42), 17609-17610.
98. Belyi, V. A., Ak, P., Markert, E., Wang, H., Hu, W., Puzio-Kuter, A., et al. (2010). The origins and evolution of the p53 family of genes. Cold Spring Harbor Perspectives in Biology, 2, a001198.
99. Yang, A., Kaghad, M., Caput, D., & McKeon, F. (2002). On the shoulders of giants: p63, p73 and the rise of p53. Trends in Genetics, 18(2), 90-95.
100. Grespi, F., Amelio, I., Tucci, P., Annicchiarico-Petruzzelli, M., & Melino, G. (2012). Tissue-specific expression of p73 C-terminal isoforms in mice. Cell Cycle, 11(23), 4474-4483.
101. Melino, G., Bernassola, F., Ranalli, M., Yee, K., Zong, W. X., Corazzari, M., et al. (2004). p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. The Journal of Biological Chemistry, 279(9), 8076-8083.
102. Momii, Y., Izumi, H., Shiota, M., Onitsuka, T., Abe, T., Kobayashi, H., et al. (2007). p73gamma transactivates the p21 promoter through preferential interaction with the p300/CBP-associated factor in human prostate cancer cells. Oncology Reports, 18(2), 411-416.
103. Bisso, A., Collavin, L., & Del Sal, G. (2011). p73 as a pharmaceutical target for cancer therapy. Current Pharmaceutical Design, 17(6), 578-590.
104. Maas, A. M., Bretz, A. C., Mack, E., & Stiewe, T. (2013). Targeting p73 in cancer. Cancer Letters, (in press).
105. Daskalos, A., Logotheti, S., Markopoulou, S., Xinarianos, G., Gosney, J. R., Kastania, A. N., et al. (2011). Global DNA hypomethylation-induced ΔNp73 transcriptional activation in non-small cell lung cancer. Cancer Letters, 300(1), 79-86.
106. Ibrahim, N., He, L., Leong, C. O., Xing, D., Karlan, B. Y., Swisher, E. M., et al. (2010). BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Research, 70(18), 7155-7165.
107. Tuve, S., Racek, T., Niemetz, A., Schultz, J., Soengas, M. S., & Pützer, B. M. (2006). Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas. Apoptosis, 11(2), 235-243.
108. Das, S., & Somasundaram, K. (2006). Therapeutic potential of an adenovirus expressing p73 beta, a p53 homologue, against human papilloma virus positive cervical cancer in vitro and in vivo. Cancer Biology & Therapy, 5(2), 210-217.
109. Lau, L. M., Wolter, J. K., Lau, J. T., Cheng, L. S., Smith, K. M., Hansford, L. M., et al. (2009). Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene, 28(19), 2024-2033.
110. Dar, A. A., Belkhiri, A., Ecsedy, J., Zaika, A., & El-Rifai, W. (2008). Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Research, 68(21), 8998-9004.
111. Rosenbluth, J. M., Mays, D. J., Pino, M. F., Tang, L. J., & Pietenpol, J. A. (2008). A gene signature-based approach identifies mTOR as a regulator of p73. Molecular and Cellular Biology, 28(19), 5951-5964.
112. Di Vinci, A., Sessa, F., Casciano, I., Banelli, B., Franzi, F., Brigati, C., et al. (2009) Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer. International Journal of Oncology, 34(2), 449-456.
113. Casciano, I., Banelli, B., Croce, M., Allemanni, G., Ferrini, S., Tonini, G. P., et al. (2002). Role of methylation in the control of DeltaNp73 expression in neuroblastoma. Cell Death and Differentiation, 9(3), 343-345.
114. Buhlmann, S., & Pützer, B. M. (2008). DNp73 a matter of cancer: mechanisms and clinical implications. Biochimica et Biophysica Acta, 1785(2), 207-216.
115. Liu, S. S., Chan, K. Y., Cheung, A. N., Liao, X. Y., Leung, T. W., & Ngan, H. Y. (2006). Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clinical Cancer Research, 12(13), 3922-3927.
116. White, E., & Prives, C. (1999). DNA damage enables p73. Nature, 399(6738), 734-735, 737.
117. Zoumpourlis, V., Solakidi, S., Papathoma, A., & Papaevangeliou, D. (2003). Genetic alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis. Carcinogenesis, 24(7), 1159-1165.
118. David, C. J., & Manley, J. L. (2010). Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes & Development, 24(21), 2343-2364.